Aldeyra Therapeutics ( $ALDX ): past, present and future around reproxalap and the March 2026 FDA decision

A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision.

ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real

Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.”

Firefly Aerospace Inc ( $FLY ) March 12 2026

Thursday’s move in Firefly Aerospace was not just a momentum spike on a cool rocket headline. The market reacted because Alpha Flight 7 checked several boxes at once. Firefly did not merely launch. It reached orbit, delivered a Lockheed Martin technology demonstrator, completed a stage-two engine relight, and used the mission to validate meaningful pieces of its next hardware iteration, Alpha Block II. In the space business, especially for a newer public company still earning its institutional reputation, those are not cosmetic details.

BlackSky (NYSE: $BKSY) — why the story looks stronger in March 2026

BlackSky has turned a familiar speculative space name into something the market is finally trying to reprice as real defense-tech infrastructure. Fourth-quarter numbers were solid, backlog expanded, a new seven-figure NGA Luno delivery order added another official validation point, and then management followed with two operational milestones that matter more than the typical space-company headline: Gen-3 first light arrived within hours, and the fourth Gen-3 satellite was commissioned in less than a week, opening general availability of the company’s best-in-class 35-centimeter imagery and AI-enabled analytics to global customers. The bullish case is no longer based only on a distant dream of “space growth.” It is increasingly built on the idea that BlackSky is becoming a usable, taskable, software-connected intelligence layer for governments that need decisions faster, not just prettier satellite pictures.

Artiva Biotherapeutics Inc ( $ARTV ) March 11th

Artiva Biotherapeutics rallied sharply after its full-year 2025 results and business update put the spotlight back where biotech traders care most: near-term clinical readouts, FDA path visibility, analyst support, and whether the balance sheet is strong enough to carry the story into the next real value-inflection point.

Hims & Hers ( $HIMS ) from GLP-1 backlash to a big strategic reset

A few weeks ago the core question was whether Hims had pushed the GLP-1 trade too far and invited a regulatory and legal backlash that could damage one of the market’s favorite growth stories. That question has not disappeared. But the story has changed meaningfully. The company now has a formal strategic shift in U.S. weight loss, a public collaboration with Novo Nordisk, access to branded Wegovy and Ozempic on the platform, a dropped lawsuit, and still the pending Eucalyptus acquisition that could reshape the company from a fast U.S. telehealth operator into a broader global consumer-health platform.

Ocugen Inc ( $OCGN ) why the stock exploded, what the dual analyst boost really means

Ocugen came back to life on a violent session after a stacked sell-side day: one firm initiated with an Outperform and a $10 target, while another raised its target to $22 from $15 and kept a Buy rating. But the move does not sit on analyst language alone. It lands on top of a Phase 3 enrollment-complete lead program, a visible BLA path, multiple ocular follow-on catalysts, a high-beta retail base, meaningful short interest, and a balance sheet that is improved from panic but still nowhere near bulletproof.

Planet Labs ( $PL )moving toward strategic infrastructure

The new delay on Middle East imagery is not enough, by itself, to make a full article. But as an editorial trigger, it is strong. It forces a bigger question: is Planet still mainly a commercial satellite-imagery company, or is it becoming a strategic information utility that increasingly operates inside the security architecture of the United States and its allies?

X and the Nasdaq question

A careful bilingual deep dive on whether X could realistically find a route to Nasdaq exposure after today’s Reuters reports, why the answer is more indirect than many headlines suggest, and how payments, regulation, competition and corporate structure change the picture.

Castellum ($CTM) — 2025 repaired the story

Castellum came out of 2025 looking cleaner, less leveraged and more credible than it did a year earlier. Revenue grew, operating losses narrowed sharply, cash improved, debt was almost fully gone by year-end and then fully eliminated shortly after. The central question now is no longer whether CTM can tell a better story, but whether it can turn backlog, contract wins and pipeline into durable margins and more repeatable cash generation in 2026.

ImmunityBio (NASDAQ: IBRX) — FDA resubmission

What happened today
Today’s real headline is straightforward: ImmunityBio announced that it has resubmitted the supplemental biologics license application to the FDA for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.

According to the company, it had already submitted information requested by the FDA in February 2026, but in March the agency then requested updated efficacy information based on longer follow-up, which ImmunityBio says has now been included in the resubmitted package.

Ondas (NASDAQ: $ONDS) — preliminary 2025 earnings beat and Mistral merger agreement Updated mach 10

A long-form bilingual deep dive on what changed in Ondas’ preliminary fourth-quarter and full-year 2025 update, why the revenue beat matters more than the raw numbers alone, how the Mistral agreement changes the strategic map, and what investors should watch next as ONDS tries to move from fast-growing defense-tech vendor to a broader autonomous systems platform with prime-contractor access.